Carolina Sciortino

Closest collaborators

The 23 strongest of 23 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

1. Monica Niger · 3 shared papers, 2025–2026 · strength 0.67
   • Paper Precision Medicine in Pancreatic Cancer: Targeting KRAS and Beyond. DOI 10.1007/s11523-026-01236-x↗
   • Paper Impact of diabetes mellitus on treatment efficacy in patients with advanced pancreatic cancer: the Italian, multicenter… DOI 10.1016/j.esmogo.2025.100276↗
   • Paper A phase III randomized clinical trial of Gemcitabine and Nab-Paclitaxel as switch maintenance versus continuation of mo… DOI 10.1016/j.dld.2025.11.007↗
2. Federico Nichetti · 2 shared papers, 2025–2026 · strength 0.37
   • Paper Impact of diabetes mellitus on treatment efficacy in patients with advanced pancreatic cancer: the Italian, multicenter… DOI 10.1016/j.esmogo.2025.100276↗
   • Paper A phase III randomized clinical trial of Gemcitabine and Nab-Paclitaxel as switch maintenance versus continuation of mo… DOI 10.1016/j.dld.2025.11.007↗
3. Caterina Vivaldi · 2 shared papers, 2025–2026 · strength 0.37
   • Paper Impact of diabetes mellitus on treatment efficacy in patients with advanced pancreatic cancer: the Italian, multicenter… DOI 10.1016/j.esmogo.2025.100276↗
   • Paper A phase III randomized clinical trial of Gemcitabine and Nab-Paclitaxel as switch maintenance versus continuation of mo… DOI 10.1016/j.dld.2025.11.007↗
4. Lisa Salvatore · 2 shared papers, 2025–2026 · strength 0.37
   • Paper Impact of diabetes mellitus on treatment efficacy in patients with advanced pancreatic cancer: the Italian, multicenter… DOI 10.1016/j.esmogo.2025.100276↗
   • Paper A phase III randomized clinical trial of Gemcitabine and Nab-Paclitaxel as switch maintenance versus continuation of mo… DOI 10.1016/j.dld.2025.11.007↗
5. Wungki Park · 1 shared paper, 2026 · strength 0.30
   • Paper Precision Medicine in Pancreatic Cancer: Targeting KRAS and Beyond. DOI 10.1007/s11523-026-01236-x↗
6. Hendrik Schürmann · 1 shared paper, 2026 · strength 0.30
   • Paper Precision Medicine in Pancreatic Cancer: Targeting KRAS and Beyond. DOI 10.1007/s11523-026-01236-x↗
7. Maximilian Reichert · 1 shared paper, 2026 · strength 0.30
   • Paper Precision Medicine in Pancreatic Cancer: Targeting KRAS and Beyond. DOI 10.1007/s11523-026-01236-x↗
8. Grainne Mary O'Kane · 1 shared paper, 2026 · strength 0.30
   • Paper Precision Medicine in Pancreatic Cancer: Targeting KRAS and Beyond. DOI 10.1007/s11523-026-01236-x↗
9. Kenneth P. Olive · 1 shared paper, 2026 · strength 0.30
   • Paper Precision Medicine in Pancreatic Cancer: Targeting KRAS and Beyond. DOI 10.1007/s11523-026-01236-x↗
10. Christoph Benedikt Westphalen · 1 shared paper, 2026 · strength 0.30
    • Paper Precision Medicine in Pancreatic Cancer: Targeting KRAS and Beyond. DOI 10.1007/s11523-026-01236-x↗
11. Mario Scartozzi · 1 shared paper, 2026 · strength 0.21
    • Paper Impact of diabetes mellitus on treatment efficacy in patients with advanced pancreatic cancer: the Italian, multicenter… DOI 10.1016/j.esmogo.2025.100276↗
12. Andrea Pretta · 1 shared paper, 2026 · strength 0.21
    • Paper Impact of diabetes mellitus on treatment efficacy in patients with advanced pancreatic cancer: the Italian, multicenter… DOI 10.1016/j.esmogo.2025.100276↗
13. Vincenzo Mazzaferro · 1 shared paper, 2026 · strength 0.21
    • Paper Impact of diabetes mellitus on treatment efficacy in patients with advanced pancreatic cancer: the Italian, multicenter… DOI 10.1016/j.esmogo.2025.100276↗
14. P. Andena · 1 shared paper, 2026 · strength 0.21
    • Paper Impact of diabetes mellitus on treatment efficacy in patients with advanced pancreatic cancer: the Italian, multicenter… DOI 10.1016/j.esmogo.2025.100276↗
15. Giampaolo Tortora · 1 shared paper, 2026 · strength 0.21
    • Paper Impact of diabetes mellitus on treatment efficacy in patients with advanced pancreatic cancer: the Italian, multicenter… DOI 10.1016/j.esmogo.2025.100276↗
16. Francesco Leone · 1 shared paper, 2025 · strength 0.16
    • Paper A phase III randomized clinical trial of Gemcitabine and Nab-Paclitaxel as switch maintenance versus continuation of mo… DOI 10.1016/j.dld.2025.11.007↗
17. Elisa Giommoni · 1 shared paper, 2025 · strength 0.16
    • Paper A phase III randomized clinical trial of Gemcitabine and Nab-Paclitaxel as switch maintenance versus continuation of mo… DOI 10.1016/j.dld.2025.11.007↗
18. Emanuela Dell’Aquila · 1 shared paper, 2025 · strength 0.16
    • Paper A phase III randomized clinical trial of Gemcitabine and Nab-Paclitaxel as switch maintenance versus continuation of mo… DOI 10.1016/j.dld.2025.11.007↗
19. Silvia Bozzarelli · 1 shared paper, 2025 · strength 0.16
    • Paper A phase III randomized clinical trial of Gemcitabine and Nab-Paclitaxel as switch maintenance versus continuation of mo… DOI 10.1016/j.dld.2025.11.007↗
20. Francesca Bergamo · 1 shared paper, 2025 · strength 0.16
    • Paper A phase III randomized clinical trial of Gemcitabine and Nab-Paclitaxel as switch maintenance versus continuation of mo… DOI 10.1016/j.dld.2025.11.007↗
21. Ingrid Garajová · 1 shared paper, 2025 · strength 0.16
    • Paper A phase III randomized clinical trial of Gemcitabine and Nab-Paclitaxel as switch maintenance versus continuation of mo… DOI 10.1016/j.dld.2025.11.007↗
22. Ilario Giovanni Rapposelli · 1 shared paper, 2025 · strength 0.16
    • Paper A phase III randomized clinical trial of Gemcitabine and Nab-Paclitaxel as switch maintenance versus continuation of mo… DOI 10.1016/j.dld.2025.11.007↗
23. Gianluca Tomasello · 1 shared paper, 2025 · strength 0.16
    • Paper A phase III randomized clinical trial of Gemcitabine and Nab-Paclitaxel as switch maintenance versus continuation of mo… DOI 10.1016/j.dld.2025.11.007↗

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.